Literature DB >> 2060552

Pitfalls of pharmacokinetic dosage guidelines in renal insufficiency.

K Turnheim1.   

Abstract

As the renal elimination of most drugs is closely correlated with the endogenous creatinine clearance, it is possible to use this parameter of kidney function to adjust drug dosage in renal failure. However, this simple procedure neglects possible changes in the volume of distribution, plasma protein binding, drug metabolism, intestinal absorption, and pharmacodynamics in renal insufficiency, as well as the occurrence of biologically active drug metabolites. Because of these uncertainties in critical cases the validity of the dosage calculated using the creatinine clearance should be checked by clinical surveillance and measurements of drug blood concentrations. Further, pharmacokinetic dosage guidelines based on the individual creatinine clearance may not be applicable to diuretics and drugs which have markedly differing kinetics of pharmacodynamic effects and blood levels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060552     DOI: 10.1007/bf00315145

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  53 in total

1.  Drug distribution and renal failure.

Authors:  M Gibaldi; D Perrier
Journal:  J Clin Pharmacol New Drugs       Date:  1972 May-Jun

2.  Unique biosynthesis by kidney of a biological active vitamin D metabolite.

Authors:  D R Fraser; E Kodicek
Journal:  Nature       Date:  1970-11-21       Impact factor: 49.962

3.  Relationship between renal clearance of drugs and glomerular filtration rate in patients with chronic renal insufficiency.

Authors:  O Schück; H Nádvorníková; J Grafnetterová; V Reitschlägerová
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1985-04

4.  Clinical use of furosemide.

Authors:  F C Reubi
Journal:  Ann N Y Acad Sci       Date:  1966-11-22       Impact factor: 5.691

5.  Comparison of the short-term effects of the loop diuretic piretanide and furosemide in patients with renal insufficiency.

Authors:  C Marone; F C Reubi; W Lahn
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Pindolol availability in hypertensive patients with normal and impaired renal function.

Authors:  N P Chau; Y A Weiss; M E Safar; D E Lavene; D R Georges; P L Milliez
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

Review 7.  Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 8.  Drug dosage in renal disease.

Authors:  L Dettli
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Furosemide kinetics in renal failure.

Authors:  W J Tilstone; A Fine
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

Review 10.  Drug prescribing in renal failure: dosing guidelines for adults.

Authors:  W M Bennett; G R Aronoff; G Morrison; T A Golper; J Pulliam; M Wolfson; I Singer
Journal:  Am J Kidney Dis       Date:  1983-11       Impact factor: 8.860

View more
  5 in total

1.  Physiological modelling of renal drug clearance.

Authors:  I Janků
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Pharmacokinetics of indomethacin in the elderly.

Authors:  R Oberbauer; P Krivanek; K Turnheim
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

3.  Drug dosing guidelines in patients with renal failure.

Authors:  S K Swan; W M Bennett
Journal:  West J Med       Date:  1992-06

Review 4.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

5.  Renal function, bisphenol A, and alkylphenols: results from the National Health and Nutrition Examination Survey (NHANES 2003-2006).

Authors:  Li You; Xiangzhu Zhu; Martha J Shrubsole; Hong Fan; Jing Chen; Jie Dong; Chuan-Ming Hao; Qi Dai
Journal:  Environ Health Perspect       Date:  2010-12-08       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.